Plasma microRNA miR-26b as a potential diagnostic biomarker of degenerative myelopathy in Pembroke welsh corgis.
Canine
Degenerative myelopathy
Diagnostic biomarker
Neurology
microRNA
Journal
BMC veterinary research
ISSN: 1746-6148
Titre abrégé: BMC Vet Res
Pays: England
ID NLM: 101249759
Informations de publication
Date de publication:
10 Jun 2019
10 Jun 2019
Historique:
received:
09
06
2018
accepted:
04
06
2019
entrez:
12
6
2019
pubmed:
12
6
2019
medline:
10
7
2019
Statut:
epublish
Résumé
Degenerative myelopathy (DM) is a progressive neurodegenerative disease frequently found in Pembroke Welsh Corgis (PWCs). Most DM-affected PWCs are homozygous for the mutant superoxide dismutase 1 (SOD1) allele; however, the genetic examination for the SOD1 mutation does not exclusively detect symptomatic dogs. In order to identify novel biomarkers, the plasma microRNA (miRNA) profiles of PWCs with DM were investigated. Quantification of the plasma levels of 277 miRNAs by an RT-qPCR array identified 11 up-regulated miRNAs and 7 down-regulated miRNAs in DM-affected PWCs from those in wild-type SOD1 PWCs. A pathway analysis identified 3 miRNAs: miR-26b, miR-181a, and miR-196a, which potentially regulate several genes associated with SOD1. In order to validate the diagnostic accuracy of the candidate miRNAs in the aged PWC population, candidate miRNAs in plasma were measured by RT-qPCR and a receiver operating characteristic (ROC) curve analysis was performed. miR-26b had the largest area under the ROC curve for distinguishing DM PWCs from healthy PWCs (sensitivity, 66.7%; specificity, 87.0%). The plasma level of miR-26b was significantly higher in the DM group than in the healthy control group. A positive correlation was observed between increases in the plasma level of miR-26b and disease progression. These results suggest that plasma miR-26b is a potential novel diagnostic biomarker of DM.
Sections du résumé
BACKGROUND
BACKGROUND
Degenerative myelopathy (DM) is a progressive neurodegenerative disease frequently found in Pembroke Welsh Corgis (PWCs). Most DM-affected PWCs are homozygous for the mutant superoxide dismutase 1 (SOD1) allele; however, the genetic examination for the SOD1 mutation does not exclusively detect symptomatic dogs. In order to identify novel biomarkers, the plasma microRNA (miRNA) profiles of PWCs with DM were investigated.
RESULTS
RESULTS
Quantification of the plasma levels of 277 miRNAs by an RT-qPCR array identified 11 up-regulated miRNAs and 7 down-regulated miRNAs in DM-affected PWCs from those in wild-type SOD1 PWCs. A pathway analysis identified 3 miRNAs: miR-26b, miR-181a, and miR-196a, which potentially regulate several genes associated with SOD1. In order to validate the diagnostic accuracy of the candidate miRNAs in the aged PWC population, candidate miRNAs in plasma were measured by RT-qPCR and a receiver operating characteristic (ROC) curve analysis was performed. miR-26b had the largest area under the ROC curve for distinguishing DM PWCs from healthy PWCs (sensitivity, 66.7%; specificity, 87.0%). The plasma level of miR-26b was significantly higher in the DM group than in the healthy control group. A positive correlation was observed between increases in the plasma level of miR-26b and disease progression.
CONCLUSIONS
CONCLUSIONS
These results suggest that plasma miR-26b is a potential novel diagnostic biomarker of DM.
Identifiants
pubmed: 31182094
doi: 10.1186/s12917-019-1944-3
pii: 10.1186/s12917-019-1944-3
pmc: PMC6558770
doi:
Substances chimiques
Biomarkers
0
MicroRNAs
0
Superoxide Dismutase-1
EC 1.15.1.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
192Références
Prog Neurobiol. 2003 May;70(1):1-32
pubmed: 12927332
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
EMBO J. 2005 Dec 7;24(23):3996-4006
pubmed: 16252002
J Vet Intern Med. 2007 Nov-Dec;21(6):1323-31
pubmed: 18196743
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2794-9
pubmed: 19188595
Vet Clin North Am Small Anim Pract. 2010 Sep;40(5):929-50
pubmed: 20732599
J Vet Med Sci. 2011 Oct;73(10):1275-9
pubmed: 21628865
J Vet Intern Med. 2011 Sep-Oct;25(5):1166-70
pubmed: 21848967
J Vet Med Sci. 2013;75(6):795-8
pubmed: 23328634
Exp Neurol. 2013 Oct;248:1-9
pubmed: 23707216
Front Cell Neurosci. 2013 Sep 10;7:150
pubmed: 24058335
J Vet Intern Med. 2014 Mar-Apr;28(2):515-21
pubmed: 24524809
Vet J. 2014 May;200(2):312-7
pubmed: 24662024
Adv Genet. 2014;85:149-99
pubmed: 24880735
Brain. 2014 Nov;137(Pt 11):2938-50
pubmed: 25193138
Forensic Sci Int Genet. 2015 Jan;14:1-10
pubmed: 25280377
J Mol Neurosci. 2015 May;56(1):102-12
pubmed: 25433762
Vet Pathol. 2015 Nov;52(6):1099-107
pubmed: 25732177
Neuroscience. 2015 Sep 10;303:229-40
pubmed: 26162235
Zoology (Jena). 2016 Feb;119(1):64-73
pubmed: 26432396
Mol Brain. 2015 Oct 24;8(1):67
pubmed: 26497046
Int J Mol Sci. 2015 Oct 23;16(10):25377-91
pubmed: 26512652
Front Cell Neurosci. 2015 Dec 17;9:476
pubmed: 26733805
J Vet Med Sci. 2016 Sep 1;78(8):1323-7
pubmed: 27109068
Proc Natl Acad Sci U S A. 2016 May 31;113(22):E3091-100
pubmed: 27185954
J Neurol Sci. 2016 Sep 15;368:19-24
pubmed: 27538595
J Clin Diagn Res. 2016 Jul;10(7):KE01-6
pubmed: 27630867
Vet J. 2016 Oct;216:122-4
pubmed: 27687938
J Neurol Sci. 2017 Jan 15;372:369-378
pubmed: 27838005
J Vet Intern Med. 2017 Mar;31(2):513-520
pubmed: 28186658
Mol Neurobiol. 2018 Mar;55(3):2617-2630
pubmed: 28421535
Alzheimers Res Ther. 2017 Nov 09;9(1):89
pubmed: 29121998
Front Mol Neurosci. 2017 Oct 31;10:352
pubmed: 29163029
J Am Vet Med Assoc. 1973 Jun 15;162(12):1045-51
pubmed: 4196853